Enrico Martin

85 Treatment and survival in pediatric MPNST 46. Haas RL, Gronchi A, van de Sande MAJ, et al. Perioperative Management of Extremity Soft Tissue Sarcomas. J Clin Oncol . 2018;36(2):118-124. doi:10.1200/ JCO.2017.74.7527 47. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol . 2001;19(5):1238-1247. doi:10.1200/ JCO.2001.19.5.1238 48. Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus s tandard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol . 2017;18(6):812-822. doi:10.1016/S1470-2045(17)30334-0 49. Martin E, Lamba N, Flucke UE, et al. Non-cytotoxic systemic treatment in malignant peripheral nerve sheath tumors (MPNST): A systematic review from bench to bedside. Crit Rev Oncol Hematol . 2019;138:223-232. doi:10.1016/j. critrevonc.2019.04.007 50. Albritton KH, Rankin C, Coffin CM, et al. Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). J Clin Oncol . 2006;24(18_suppl):9518. doi:10.1200/ jco.2006.24.18_suppl.9518 51. Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol . 2009;27(19):3148-3153. doi:10.1200/JCO.2008.20.5054 52. Maki RG, D’Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol . 2009;27(19):3133-3140. doi:10.1200/JCO.2008.20.4495 53. Widemann BC, Meyer CF, Cote GM, et al. SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST). J Clin Oncol . 2016;34(15_suppl):11053. doi:10.1200/JCO.2016.34.15_suppl.11053 54. Dickson MA, Mahoney MR, Tap WD, et al. Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma. Ann Oncol Off J Eur Soc Med Oncol . 2016;27(10):1855- 1860. doi:10.1093/annonc/mdw281 55. Schuetze SM, Wathen JK, Lucas DR, et al. SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer . 2016;122(6):868-874. doi:10.1002/ cncr.29858 56. Miettinen MM, Antonescu CR, Fletcher CDM, et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum Pathol . 2017;67:1-10. doi:10.1016/j.humpath.2017.05.010 57. Martin E, Muskens IS, Coert JH, Smith TR, Broekman MLD. Treatment and survival differences across tumor sites in malignant peripheral nerve sheath tumors: a SEER database analysis. Neuro- Oncology Pract . 2018:1-10. 4